Search

Home > New FDA Approvals > 106 - NCCN recs go beyond FDA-approved indications; 'Right to Try' bill for terminally ill patients fails in the House; CRISPR helps identify genes for ALS and dementia
Podcast: New FDA Approvals
Episode:

106 - NCCN recs go beyond FDA-approved indications; 'Right to Try' bill for terminally ill patients fails in the House; CRISPR helps identify genes for ALS and dementia
Category: Science & Medicine
Duration: 00:09:18
Publish Date: 2018-03-14 07:00:00
Description:

March 14, 2018

Please subscribe, rate and review if you like this podcast. Thank you! The podcast website is http://newfdaapprovals.com

1:16 NCCN recs go beyond FDA-approved indications https://www.renalandurologynews.com/urology/national-comprehensive-cancer-network-recommendations-beyond-fda-indications/article/750145/

http://www.bmj.com/content/360/bmj.k668

3:17 'Right to Try' bill for terminally ill patients fails in the House https://www.cnn.com/2018/03/13/politics/right-to-try-house-bill/index.html 

5:08 CRISPR helps find new genetic suspects behind amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) https://www.nih.gov/news-events/news-releases/crispr-helps-find-new-genetic-suspects-behind-als-ftd

https://www.nature.com/articles/s41588-018-0070-7

8:34 Please check out my weekly podcast AI in Medicine. In this week’s episode, I talk to Professor Peter Donnelly, CEO and founder of Genomics PLC, a group of leading geneticists and data scientists out of Oxford University, UK. They are starting to link genomic data with electronic health records to glean previously unseen insights into genetics and health outcomes. Podcast website is aimedicinenews.com.http://aimedicinenews.com/

Music credit: freemusicarchive.org/music/MindsEye/Yellow_Taxi/
Total Play: 0